News Releases

Date	Title	Additional Formats
August 29, 2024	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
August 19, 2024	Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants
August 8, 2024	Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
July 30, 2024	Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients
July 29, 2024	Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024
July 18, 2024	Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
May 28, 2024	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
May 15, 2024	Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
May 9, 2024	Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
April 29, 2024	Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024